A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone

Trial Profile

A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2015

At a glance

  • Drugs Blonanserin (Primary) ; Risperidone
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Sumitomo Dainippon Pharma
  • Most Recent Events

    • 27 Sep 2013 Based on positive results in this trial, an application for registration of blonanserin for the treatment of schizophrenia has been submitted in China, according to a Dainippon Sumitomo Pharma media release.
    • 14 Nov 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 14 Nov 2012 Planned End Date changed from 1 Nov 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top